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There  is increasing  evidence  to indicate  that  a substantial  number  of  both  man-made  and  naturally
occurring  chemicals  are  disruptive  to human  and wildlife  reproductive  health.  Currently,  reproductive
toxicology  testing  is  primarily  carried  out  in vivo,  however,  in  the  past  50 years,  various  culture  methods
have  been  developed  with  the  aim  of growing  ovarian  follicles  in  vitro.  These  culture  systems  have  become
a  widely  used  tool  in  reproductive  biology  and  toxicology.  In this  review  we describe  how  reproductive
toxicology  of  the  ovary  is greatly  enhanced  by  in  vitro  studies.  Experiments  using  in vitro  ovarian  culturesvary
ollicle
issue culture
n vitro
oxicology
harmaceutical
to  understand  or detect  damage  to the  ovary  itself  and  to its  specialised  structures  of the  follicles  and
oocytes,  allows  for faster  screening  of  potential  developmental  and/or  reproductive  toxicants.
©  2014  The  Authors.  Published  by  Elsevier  Inc. This  is  an open  access  article  under  the  CC  BY  license
(http://creativecommons.org/licenses/by/3.0/).DC
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. Introduction
.1. The ovary
The ovary is central to female reproductive function, the site
ithin which germ cells form follicles, develop and mature (Fig. 1).
hese cells communicate with each other and with ovarian stromal
ells. Mammalian oocytes develop from primordial germ cells dur-
ng gestation [1]. Following the proliferative stage, primordial germ
ells then enter a pre-meiotic state of DNA replication before enter-
ng prophase I of meiosis. They then progress through the initial
tages of meiosis, before entering meiotic arrest, around the time
f follicle formation (Fig. 2) [2,3]. The oocytes remain in this meioti-
ally arrested state throughout the phase of follicular development,
hus the growing ovarian follicle contains an oocyte arrested in
rophase I of meiosis, surrounded by somatic cells (granulosa and
heca cells) as well as a basement membrane (BM). In the post-
ubertal ovary in particular, as an oocyte grows and matures, its
ollicle undergoes changes due to proliferation of the granulosa
ells and formation of the ﬂuid ﬁlled antral cavity, resulting in a dra-
atic increase in follicle size. Once it has reached full maturation,
he pre-ovulatory, Graaﬁan follicle expels its oocyte during ovula-
ion, at which point the oocyte exits meiotic arrest and completes
eiosis I.
The ovary is not only responsible for producing oocytes, but is
lso an important endocrine gland, the source of sex steroids which
ink reproductive and non-reproductive organs to the timing of
he ovarian cycle. It is in the growing follicle that the majority of
strogens in the body are produced and once the oocyte has been
vulated, the remainder of the follicle becomes a corpus luteum
CL), a temporary endocrine structure secreting the progesterone
ritical for the establishment and initial maintenance of pregnancy.
he ovary is responsive to hormones secreted from the anterior
ituitary, in turn controlled by the hypothalamus, with which it
s locked into a complex cyclical pattern of communication and
eedback that underpins successful female reproduction. Ovarian
ollicles are dependent on both external and internal hormones
or their growth, development, maturation and ovulation. Follicle
rowth through the primordial, primary and secondary stages is
onadotropin-independent, regulated primarily by oocyte-derived
actors such as growth differentiation factor 9 (GDF9), bone mor-
hogenetic protein 15 (BMP15) and local somatic-derived factors
uch as anti-Mullerian hormone (AMH) [4]. Once a follicle tran-
its into the pre-antral stage, its growth to the early-antral stage
s gonadotropin responsive, with further growth dependent on
onadotropins [5].
In recent years, both environmental and synthetic pharma-
eutical compounds with endocrine-mimicking, -modulating or . . . . .  . . .  . .  . . .  . .  . . .  . . . . .  . .  . . . . . . .  .  . . . . . . .  . . . . . .  .  . . . .  . . . . .  .  . . .  .  .  .  . . . . . . . . . .  131
-inhibiting ability have become an increasing health concern. These
compounds have reported harmful effects on gamete development
and on the developing foetus and neonate [6]. Their relevance to
human pregnancy has been identiﬁed in a recent opinion paper
from the Royal College of Obstetricians and Gynaecologists (RCOG)
which also highlighted the issue of exposure to multiple sources of
chemicals. That paper outlined the potential reproductive hazards
associated with exposure to the developing foetus of chemicals
with the potential to interfere with foetal germ cells in the devel-
oping ovary, the effects of which would only manifest in the F2
generations, thus not becoming evident until decades later [7].
Various toxicological studies have been carried out on differ-
ent animal models both in vivo and in vitro in order to investigate
their effects on the female reproductive system [8]. Both types of
toxicology testing have advantages and limitations, which must be
carefully considered when planning a toxicological study. Here, we
review the role of in vitro studies in the examination of toxicolog-
ical effects on the ovary, comparing results from such methods to
the effects of ‘real-life’, in vivo, exposure.
2. Toxicology and reproductive function
The environmental toxicants and pharmaceuticals of concern
regarding reproductive function are from a broad spectrum of
chemicals. One group in particular, endocrine disrupting com-
pounds (EDCs), constitute a major focus. EDCs have been described
by the United States Environmental Protection agency (USEPA) as
agents that ‘interfere with synthesis, secretion, transport, binding
or elimination of natural hormones in the body that are respon-
sible for maintenance of homeostasis, reproduction, development
and/or behaviour’ [9]. Pharmaceutical and chemical companies
produce novel chemicals in the form of new drugs, and widely used
industrial and agricultural compounds, which can, in some cases,
act as EDCs [10]. Humans are exposed to thousands of these natural
or man-made chemicals throughout their lifespan [6,10–12]. Some
are ingested as drugs or absorbed through the skin via beauty prod-
ucts such as soaps and perfumes [10], whereas others can leach out
of plastic or be inhaled from cigarette smoke, pollution or vehicle
exhausts (Table 1).
There is increasing evidence suggesting that certain pharma-
ceuticals and EDCs have the potential to interfere with endocrine
function, biosynthesis or homeostatic control, alter reproductive
development and fertility and result in reproductive disorders
[13,14]. Reproductive toxicants can interfere with endocrine mech-
anisms due to their weak intrinsic hormonal activity, most often
by mimicking or inhibiting estrogens through binding to nuclear,
membrane, neurotransmitter and/or orphan receptors.
A. Stefansdottir et al. / Reproductive Toxicology 49 (2014) 117–135 119
Fig. 1. Follicle growth in a human ovary. Proliferating primordial germ cells (PGCs) migrate to, and invade the developing ovary to form germ cell nests. They proliferate at a
high  rate, then enter meiosis and form primordial follicles as the germ cell nests break down. Throughout the reproductive lifespan, small cohorts of primordial follicles are
continually released from dormancy as they enter the growing pool. The vast majority of growing follicles are lost to atresia, but beginning at puberty, a few follicles grow
to  the Graaﬁan stage, normally resulting in the release of one oocyte each menstrual cycle. The remainder of the ovulatory follicle forms the corpus luteum (CL).
Fig. 2. Meiosis in oocytes. Stages and phases of mammalian meiosis, including two  meiotic arrests during prophase I and metaphase II. The ﬁgure demonstrates chromosomal
behaviour during meiotic progression in the mouse and human, with the time-course of events leading to the formation of an arrested oocyte within the growing follicle
and  ultimately, a mature fertilised oocyte.
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Table 1
Overview of some of the most common EDCs and their sources.
EDCs Exposures and uses References
Alkyl phenol Detergents, cosmetics, paints [15]
Bisphenol A (BPA) Polyester–styrene resins, plastic food containers, baby bottles, eating utensils [16]
Chlordane Insecticide [16]
Dioxins Paper manufacturing, herbicides, incinerators [16]
DDT and MXC Organochlorine pesticides [8]
Heavy metals (cadmium, lead, mercury) Batteries, pigments, pharmaceuticals, plastic stabilisers, burning of fossil fuels
and  the incineration of municipal waste
[16,17]
Phthalates Soft plastic chew toys, nail varnish, perfumes, ﬂavourings and solvents [16,18]
Phyto-estrogens Soy, grains [16]
Polybrominated diphenyl ethers (PBDEs) Flame retardants [16]
Polychlorinated biphenyls (PCBs) Flame retardants, adhesives, electrical transformers [15,16]
Polycyclic aromatic hydrocarbons (PAHs) Industrial air pollution, coal and coke burners, tobacco tar [16]
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.1. Female reproductive toxicity
Given that reproductive toxicology research is carried out not
nly in vivo, but also using in vitro cultures [22], the main focus
f this review is to examine and compare effects of compounds
hat have been tested both in vivo and in vitro. The majority of
ata reviewed will refer to EDCs since they have been more widely
eported in female reproductive toxicology research in both in vivo
nd in vitro studies. In contrast, there is relatively little information
n the effects of pharmaceutical compounds in vitro, other than
n the examination of the effects of chemotherapy agents on the
vary. Chemotherapy agents can, none-the-less, have very impor-
ant effects on the ovary [23,24].
Human epidemiological studies have shown an association
etween exposure to EDCs during development and adverse
ealth outcomes in females [13,25–28]. For some chemicals,
DCs have the ability to disturb crucial pathways within the
ypothalamic–pituitary–ovary axis at all stages of life: pre-natal,
re-pubertal and adulthood [13,22,29] (Table 2). However, certain
eriods of reproductive life are more susceptible to harm by EDC
xposure than others. For example, foetuses exposed to estrogenic
roducts through soy consumption of the mother and subse-
uently transferred via the placenta are more vulnerable than those
xposed as adults, particularly if exposure to the estrogenic agents
n soy products is at the critical period of germ cell nest break-
own and entry of PGCs into meiosis [30,31]. Between 1940 and
970, pregnant women at risk of miscarriage were prescribed the
eno-oestrogen diethylstilbestrol (DES) [32]. Foetuses are exposed
o endogenous oestrogen throughout pregnancy, but girls exposed
o DES in utero during that critical period of reproductive tract
evelopment developed reproductive tract abnormalities and also
ad increased incidence of cervical–vaginal cancer later in life [33].
ny reproductive toxicant that has a direct effect on the ovary may
lso be able to alter epigenetic mechanisms in the oocyte, result-
ng in trans-generational epigenetic effects [31,34–37]. Therefore,
ubtle modiﬁcations to gene expression independent of gene muta-
ions are entirely possible. An example of this type of germline
ransmission of an epigenetically modiﬁed trait is suggested in
inclozolin-treated rats, although the results are somewhat con-
roversial [37–40].
.1.1. Mechanisms of action of reproductive toxicants
Pre- and post-natal ovaries contain large numbers of germ cells
nd follicles at various stages of development. Pre-natally, this
ncludes the rapidly proliferating primordial germ cells (PGCs)
nd oocytes undergoing the ﬁrst meiotic division. Drug-induced
amage at this time markedly reduces the post-natal follicle pool
41]. The mature ovary contains primordial follicles with all poten-
ially viable oocytes in meiotic arrest, dividing granulosa cellse [19]
nal care and household products [20]
tive diluent for diepoxides and epoxy resins [21]
and maturing oocytes of growing follicles, as well as ovulating
oocytes resuming meiosis. The ever-changing environment must
be carefully considered when studying the effects of environmen-
tal chemicals on the ovary, as follicles in different stages of growth
may  well vary in their susceptibility to different compounds.
Following follicle formation and growth initiation, ovarian folli-
cles enter a period of continuous development until they either
undergo atresia or develop to the Graaﬁan stage, accompanied
by rapid granulosa cell proliferation. That continual growth state,
accompanied by the meiotic arrest of the oocyte for up to 45 years
in humans, makes them particularly vulnerable targets for repro-
ductive toxicants. The somatic cells and the BM of the follicle can
be thought of as a protective sheath enclosing the oocyte, but this
does not necessarily protect it from the effect of mutagens, directly
or indirectly. The majority of toxic compounds are able to access
the ovary via the circulation, but if these toxicants are able to pass
through the BM,  then the oocyte can also potentially be affected.
Even if they directly affect only granulosa or thecal cells, they are
still able to affect the oocyte indirectly. Once in the ovary, repro-
ductive toxicants may  be further metabolised, which may  reduce
or increase the risks, depending upon the metabolites generated
[42].
Compounds targeting the primordial pool can have highly
adverse effects on fertility, with broader consequences than those
targeting growing follicles. If the primordial pool of follicles is dam-
aged, future follicle growth and ovulation will be affected. At worst,
a chemical that interferes markedly with the resting pool will likely
result in premature ovarian insufﬁciency (POI) by depleting the
ovarian reserve of primordial follicles [43]. In contrast, if a com-
pound speciﬁcally targets growing or pre-antral follicles, perhaps
by affecting dividing granulosa cells, these follicles will undergo
atresia, resulting in cyclic disturbances for the few months follow-
ing exposure to the compound. However, once the compound and
its effects are removed, new follicles (from the unaffected resting
pool) will begin growing and form normal ovulatory follicles, thus
restoring fertility [44]. Effects on growing follicles can, though, have
long-term consequences: studies into the effects of chemotherapy
on the ovary are providing growing evidence that repeated damage
to growing follicles can have a severe effect on the primordial pool,
as the loss of growing follicles leads to premature activation of pri-
mordial follicles and consequently, a depletion of the primordial
follicle pool [24,45–47].
There are several other ways in which chemicals can disrupt
oocyte development. During meiotic progression of the oocyte,
chromosomes utilise a bipolar spindle for their segregation during
both meiotic divisions. If disturbed, this will likely lead to impair-
ment in chromosome pairing or spindle formation, resulting in
non-disjunction [48]. Regulation of progression of the cell cycle is
tightly controlled by feedback mechanisms that sense disturbances
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Table  2
Overview of associations between EDCs and female reproductive dysfunction.
Chemical Effect Species References
Bisphenol A (BPA) Disturbances in spindle formation and chromosome alignment Mouse [51,53]
Multioocyte follicles Mouse [57]
Increased length of estrous cycle Mouse [68]
Cessation of estrous cycle Rat [69]
Cyclophosphamide (Cy) Disrupted ovarian folliculogenesis and altered steroid production Rat [70]
Decreased E2 levels in plasma and reduced uterine weight Mouse [71]
Destruction of antral follicles Mouse [72]
Reduced ovarian follicle numbers Mouse [41]
Cadmium Reduced germ cell population, retarded germ cell migration and poor gonadal development Mouse [73]
Diethylstilbestrol (DES) estrogenic Girls exposed in utero had increased cervico-vaginal cancers, decreased fertility and POI. Human [74–76]
Meiotic spindle defect in Meiosis II Mouse [50]
Neonatal exposure results in the absence of corpora luta, hypertrophy of interstitial ovarian
tissue and haemorrhagic cysts
Mouse [77]
Perinatal exposure induces polyovular follicles Mouse [78]
Genistein Neonatal exposure causes prolonged and abnormal cycles in adult animals Mouse [79]
Neonatal exposure causes dysfunction of post-pubertal reproductive performance and
abnormal development of female gonads
Rat [56]
Reduced progesterone synthesis Porcine [80]
Methoxychlor (MXC) Inhibition of folliculogenesis and increased AMH  production in ovary Rat [81]
Inhibited implantation and delayed embryogenesis Mouse [82]
Suppressed LH surge and irregular estrous cycles Rat [83]
Decreased sex steroid hormone levels Mouse [84]
Phthalates (DEHP/MEHP/BBP) Prolonged estrous cycles, reduced serum estradiol levels and absence of ovulation Rat [85]
Increased estradiol and progesterone production, leading to mid-gestation abortions Rat [86]
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nd by checkpoint controls that protect the cell from such errors
nd ensure that aneuploidy is prevented [49]. Failure during these
eiotic checkpoints can result in meiotic errors, and the resulting
utations introduced to the genetic material have the poten-
ial to be passed on to the subsequent generation. Studies have
een carried out on the possible effect of environmental chemi-
als on different stages of meiosis, including chromosome synapsis,
ecombination events and chromosome segregation [50,51]. These
tudies illustrated that environmentally relevant doses of bisphe-
ol A (BPA) and DES have the ability to interfere with the actions
f oestrogen receptors (ERs) [52] and cause abnormalities in the
lignment of chromosomes and spindle formation [50,53]. Estradiol
E2) inhibits germ cell nest breakdown and protects oocytes from
rogrammed cell death. Germ cell nest breakdown is an impor-
ant process and may  contribute to elimination of germ cells with
enetic anomalies [54]. Endocrine disrupting chemicals are likely
o interfere with this process, and studies looking at the actions of
2, progesterone and genistein on the newborn rodent ovary found
hat they all inhibit cyst breakdown, with binuclear oocytes and
ultioocyte follicles (MOFs) reported as a result of EDC exposure
55]. MOFs are often used as an indicator of an adverse effect, as they
re considered a likely result of disruption to germ cell nest break-
own [31,55–60]. Although the vast majority of oocytes affected by
hemicals are likely to end up becoming atretic [61], some might
orm aneuploid ovulated oocytes, with the consequent potential of
n aneuploid embryo and likely miscarriage.
Reproductive toxicants might either target the oocyte specif-
cally, or have more general effects on the surrounding somatic
ells. In either scenario, reproductive disorders can occur. The fol-
icle is a complex structure relying on interactions between the
ocyte and its somatic cells [62–66]. Granulosa and theca cells are
esponsible for hormone production within the ovary as well as
ontrolling the release of oocytes throughout the adult reproduc-
ive lifespan. This is mainly regulated through the expression of
utocrine and paracrine factors, creating intricate feedback loops
ithin the follicle that are essential for normal follicle developmentRabbit [87]
 Mouse [19,88]
and for meiotic competence of the oocyte. Due  to this complex
communication network formed by the oocyte, granulosa cells
and theca cells, together driving follicle development, a chemi-
cal affecting any one of these components will affect the whole
follicle [64]. These chemicals can also interfere with the feedback
loop between the ovaries and pituitary gland to perturb the balance
of the hypothalamic–pituitary–gonadal axis. Disruption can, there-
fore, not only have negative effects on follicle development, oocyte
maturation and ovulation, but also signiﬁcantly impair fertility by
affecting the production of ovarian hormones [67].
3. In vitro culture systems as a tool for studying
reproductive toxicology
Over the last half century, various culture methods have been
developed with the aim of growing follicles from an immature state
to fully mature, fertilizable oocytes [89–98]. These cultures have
become a widely used tool to study the development of follicles
in reproductive biology and toxicology and have been success-
fully established in mouse, rat, cattle, sheep, pig, primates and
humans [99–104]. In 1989, the ﬁrst successful in vitro pre-antral
follicle culture in rodents was  carried out, leading to the birth
of live pups from these cultured pre-antral follicles [90]. Subse-
quently, many in vitro cultures have been designed with the aim of
growing individual follicles, or whole ovaries, at varying stages of
development. These cultures include short- and long-term meth-
ods, individual pre-antral follicle cultures, granulosa cell–oocyte
complexes, co-cultures and whole ovary cultures, depending on
the endpoints required for the study [90,105]. Cultures spanning
earlier stages of ovary development have proven more challeng-
ing, and although a few studies have managed to create the culture
conditions necessary to produce live pups from immature cultured
follicles [91,92,94,95,98,106], achieving this using cultured oocytes
from a pre-meiotic stage has, to-date, been unsuccessful without
major manipulation of the follicles [94]. The details of each cul-
ture system are outside the scope of this review, but for extensive
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r Picton et al. [109].
In vitro ovary and follicle culture models allow for the possi-
ility of varying culture parameters in a highly controlled manner,
nd thus have the potential to allow a more thorough evaluation for
eproductive toxicity studies than do in vivo studies alone. Potential
ndpoints include studying the mechanisms of action of toxicants
nd how they contribute to oocyte or somatic cell damage, analy-
is of oocyte quality, effects on the establishment of the primordial
ollicle pool, and paracrine interactions [110]. Culture systems have
he potential to reveal whether the effects of the toxicants directly
ffect the ovary, with effects observed in vivo but not in vitro are
resumably indirect. The cultures can also reveal whether com-
ounds target follicles at speciﬁc stages of development and enable
eeper insight into the way toxicants might affect the chromosomal
ntegrity of the oocyte, or if they have the ability to alter hormonal
ignalling within and/or between follicles.
The culture methods available for toxicological research vary
n terms of species, follicle stage, time-course, and composition of
ulture media. Each culture system has its own pros and cons, all
equiring careful consideration before choosing the best method
or a toxicology study.
.1. Embryonic ovary culture
The majority of available culture systems involve the post-natal
vary and germ cells that have already entered meiotic arrest, but
he foetal stage of reproductive development is a crucial and sen-
itive period. It includes migration of germline stem cells, their
roliferation, and subsequent entry into the ﬁrst meiotic division,
ogether with proliferation and differentiation of the somatic com-
artment and the interaction between the germ and somatic cells.
re-meiotic germ cells, not enclosed in follicles may  well be directly
esponsive to chemicals, making foetal development a particularly
ulnerable period [41,111]. A culture system whereby embryonic
ouse ovaries, containing oogonia undergoing the ﬁrst meiotic
ivision, can be cultured intact would have the potential to provide
n important contribution to the ﬁeld of reproductive toxicology,
articularly as aneuploidy predominantly occurs during the ﬁrst
eiotic division of oocytes [112–114]. Although the development
f rodent oocytes from pre-meiotic foetal germ cells has been
ttempted [3,89,93,115–118], there has been relatively little suc-
ess in culturing them through both meiotic divisions to produce
ature oocytes, other than through the use of invasive techniques
uch as nuclear transfer [94]. An embryonic culture technique has
he potential to be a great contribution to the ﬁeld of reproductive
oxicology testing, due its capacity to demonstrate direct effects
f compounds on the foetal ovary, proliferation, entry into meiosis
nd the establishment of primordial follicle pool and early stages
f developing follicles.
.2. Rodent neonatal ovary culture
In rodent ovaries, primordial follicle assembly occurs around
he time of birth. Abnormalities in primordial follicle formation and
rowth could potentially lead to reproductive problems later in life,
uch as POF and infertility. The process of follicle formation and the
ubsequent initiation of follicle growth are two separate processes
oth covered by the culture of neonatal rodent ovaries [108]. The
eonatal ovary culture involves culturing of a whole rodent ovary
rom after birth for up to 20 days [91,92,95,119,120]. It is an appro-
riate culture system for studying the biology of primordial follicle
ssembly and the primordial-to-primary follicle transition, and isoxicology 49 (2014) 117–135
thus a valuable asset to toxicological research to identify potentially
hazardous compounds that could interfere with these processes.
3.3. Follicle or cumulus–oocyte-complex cultures
For culture of individual follicles, the required follicles are
isolated from their surrounding stroma and cultured to allow
examination of growth, development and metabolism away from
systemic inﬂuences. Whole pre-antral follicles can be isolated
from the ovaries of immature rodents and are able to survive in
culture for up to 12 days, growing from early pre-antral stages
to large Graaﬁan follicles which can then be ovulated in vitro
[91,104,110,121]. This culture system has yielded live pups from
cultured pre-antral follicles [91] and is an important culture system
for toxicology, as not only does it span the second meiotic division
of the oocyte, but it also covers the entire antral stage of follicle
development, including ovulation. It also allows for more detailed
investigation into the paracrine interactions between the oocyte
and the surrounding somatic cells and can also be used to examine
interactions between follicles [66,122,123].
4. Comparison of in vivo and in vitro effects of
pharmaceuticals and EDCs
As outlined above, chemicals that are suspected to have
endocrine disrupting properties include plasticisers (BPA, phtha-
lates, alkylphenols), polychlorinated biphenols (PCBs), organochlo-
rine pesticides (DDT and MXC), ﬂame retardants, parabens,
perﬂuorinated compounds, synthetic hormones used as phar-
maceutical drugs as well as the naturally occurring endocrine
active substances, such as isoﬂavones. Despite several cases where
environmental toxicants are thought to have inﬂuenced repro-
ductive function in various wildlife species [124], as well as a
number of in vivo exposure studies showing a potential link
between environmental compounds and reproductive abnormal-
ities [14,22,27,35,125,126], it remains difﬁcult to prove a causal
relationship. Regardless, environmental toxicants are still viewed
as contributing factors to diseases that are oestrogen-dependant,
including breast cancer and endometriosis [26,127]. Recent in vitro
research on laboratory animals also strongly point towards the
ability of different chemicals to affect the reproductive systems
[27,128–133]. This section focuses on a selected number of com-
pounds for which there are data on their effects on the female
reproductive system from both in vitro and in vivo studies. It
concentrates more on environmental compounds because they
constitute the largest component of chemicals with reported repro-
ductive effects in vivo and in vitro, with less data available on
pharmaceutical compounds, aside from the few chemotherapy
agents that have reported effects in vivo and in vitro.
4.1. Pharmaceutical compounds
4.1.1. Cyclophosphamide (Cy)
Cy is a commonly used chemotherapeutic agent with well-
recognised ovarian toxicity including follicle destruction and
lowered ovarian oestrogen production [72]. Cy causes intra- and
inter-strand DNA cross-linking, thereby interfering with cell divi-
sion. With increasing success of cancer treatments, there are
growing concerns about the long-term side effects of alkylating
agents such as cyclophosphamide on female reproductive function.
There are not many studies using animal models on the repro-
ductive effects of cyclophosphamide, but the ones that have been
carried out both in vivo and in vitro report very similar effects
(Table 3), namely, Cy results in a reduced total follicle reserve. To
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Table  3
Comparison of in vivo and in vitro effects of cyclophosphamide on the ovary.
Effect of Cy In vivo In vitro
Study Species Paper Study Species Paper
↓ total follicle reserve i.p. treatment for 20 days Rat (SD) [134] 8 day culture of PND4 ovaries with
Cy metabolites
Mouse (CD1) [135]
Single i.p. treatment of Cy Mouse (Balb/c) [136]
Pregnant females received
a  single i.p. injection on
E10.5 and E11.5
Mouse (L1 or 129) [41]
↑ apoptosis i.p. treatment for 20 days Rat (SD) [134] 8 day culture of PND4 ovaries
with Cy metabolites
Mouse (CD1) [135]
Altered steroidogenesis i.p. treatment for 20 days Rat (SD) [134]
Failed fertilisation and 6–7 week old females Mouse (Balb/c) [137]
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.p., intraperitoneal; SD, Sprague Dawley; PND, post-natal day.
he best of our knowledge, no in vitro studies have investigated the
ffect of Cy on steroidogenesis or on fertilisation rates.
.1.2. Diethylstilbestrol (DES)
DES is a non-steroidal synthetic compound functionally similar
o natural estradiol but with stronger bioactivity, and high afﬁn-
ty to ER (ESR1) [138]. It was ﬁrst synthesised in 1938 and was
hen prescribed to women between the 1940s and early 1970s as it
as believed to reduce the risk of spontaneous abortions and other
regnancy-related complications. It was also thought to improve
regnancy outcome by increasing production of placental steroid
ormones [139]. DES was in later years shown to cause reproduc-
ive abnormalities in the daughters born to these women, including
he otherwise rare clear cell adenocarcinoma of the vagina and
ervix [140]: DES was ﬁnally banned in 1971 [141]. There are many
aps in the literature where no equivalent in vitro studies have
een carried out alongside in vivo studies, and vice versa. How-
ver, in the few instances where there has been overlap, the in vivo
nd in vitro studies show consistent results, namely demonstrating
n increasing incidence of polyovular follicles in mice exposed to
ES (Table 4). In vivo and in vitro studies have not always given
onsistent results, though, with one study by Karavan [60] ﬁnd-
ng that DES decelerated follicular development in vivo, whereas
able 4
omparison of in vivo and in vitro effects of diethylstilbestrol on the ovary.
Effect of DES In vivo 
Study Species
Accelerated follicular development Pregnant mice at E15.5 injected
(s.c.). F1 females collected at PND7
Mouse
s.c. injections between PND1 and
14
Sheep 
Slowed follicular development Daily injections (s.c.) on PND1–4.
Ovaries collected on PND5
Mouse
Neonatal mice injected (s.c.) on
PND0–1
Mouse
Meiotic defects 
Altered cyst breakdown Daily injections (s.c.) on PND1–4.
Ovaries collected on PND5
Mouse
↓ cell death Neonatal mice injected (s.c.) on
PND0–1
Mouse
↑ polyovular follicles Neonatal mice injected (s.c.) on
PND0–1
Mouse
s.c. injections for 5 days from PND0 Mouse
↓ Estradiol and testosterone levels 
OCs, cumulus–oocyte complexes; PND, post-natal day; s.c., subcutaneous; SD, Sprague Dother in vivo studies by Wordinger [142] and Rivera [59] found the
opposite effect.
4.1.3. Doxorubicin
Doxorubicin (DXR) is an anthracycline chemotherapy agent
used to treat a variety of cancers including lymphomas, sarcomas,
as well as breast and ovarian cancer. It is thought to intercalate
with DNA to prevent replication and transcription, partly by inhib-
iting topoisomerase II, although its precise mechanism remains
unknown [24,144]. Studies into the effect of DXR on the ovary have
reported a large dose-dependent rise in the number of double-
strand DNA breaks in both oocytes and granulosa cells of the ovary.
Stromal and vascular damage have also been reported in exposed
ovaries, indicating induction of premature ovarian ageing not only
through damage to the germ cells but also via the somatic com-
ponents of the ovary [47,145]. Several papers have reported the
effects of DXR on the ovary in vivo, and many of their results have
been supported by in vitro studies, such as increased apoptosis of
follicles and increased stromal damage of exposed ovaries (Table 5).
4.2. Plasticisers4.2.1. Bisphenol A (BPA)
BPA is a weak environmental oestrogen whose effects have
generated considerable controversy over the last few years. It
In vitro
 Paper Study Species Paper
 [142]
[59]
 (CD1) [60]
 (C57BL/6J) [55]
Exposure of COCs during meiosis-I
and meiosis-II spindle formation
Mouse
(Balb-C)
[50]
 (CD1) [60]
 (C57BL/6J) [55]
 (C57BL/6J) [55] PND0 ovaries cultured with DES for
5  days and transplanted under the
renal capsule for 30 days
Mouse
(C57BL/Tw)
[143]
 (ICR/Jcl) [57]
PND14 ovaries collected, follicles
isolated and cultured with DES
Rat (SD) [138]
awley.
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Table 5
Comparison of in vivo and in vitro effects of doxorubicin on the ovary.
Effect of DXR In vivo In vitro
Study Species Paper Study Species Paper
↑ apoptosis of follicles Four week old mice treated
with DXR
Mouse (CD1) [146] GV oocytes cultured with DXR
for 20 min
Mouse (ICR) [47,147]
Single i.v. injection of DXR.
Ovaries collected 24 h later.
Mouse (B6D2
and FBV)
[145] Ovarian cortical pieces
cultured for 24–72 h with DXR
Human [145]
↓ ovarian size/weight 7–8 week old females injected
(i.p.) and ovaries collected 1
day or 1 month later
Mouse (ICR) [23]
↓ population of secondary and
primordial follicles
7–8 week old females injected
(i.p.) and ovaries collected 1
day or 1 month later
Mouse (ICR) [23] Ovarian cortical pieces
cultured for 24–72 h with DXR
Human [145]
Mice xenografted with human
ovarian tissue and dosed
Human [145]
Stromal damage Mice xenografted with human
ovarian tissue and dosed
Human [145] Ovarian cortical pieces
cultured for 24–72 h with DXR
Human [145]
GV, germinal vesicle; i.p., intraperitoneal; i.v., intravenous; s.c., subcutaneous; COCs, cumulus–oocyte complexes; SCID, severe combined immunodeﬁciency; SD,  Sprague
Dawley; PND, post-natal day.
Table 6
Comparison of in vivo and in vitro effects of BPA on the ovary.
Effect of BPA In vivo In vitro
Study Species Paper Study Species Paper
↑ recruitment of PMFs s.c. injections on PND 1, 3, 5
and 7. Ovaries collected on
PND8
Rat (Wistar) [158]
Meiotic defects Females exposed in utero
(E11.5–E18.5). Ovaries
collected at E18.3, PND28
Mouse (C57BL/6) [52] Chronic exposure to growing
pre-antral follicles in culture
Mouse
(C57BL/6j × CBA/Ca)
[131]
s.c. injections between PND1
and 14. Ovaries collected on
PND30
Sheep [59] BPA exposure of COCs during
meiosis-I and the formation of
meiosis-II spindle
Mouse (Balb/c) [159]
Females treated with oral
doses of BPA for 6–8 days
preceding oocyte collection on
PND28
Mouse [51] Oocytes isolated from antral
follicles exposed during in vitro
maturation
Mouse (MF1) [53]
Pregnant females exposed BPA
during GD 50–100. Ovaries
collected at GD 100
Rhesus monkey [160]
Delayed cyst
breakdown/MOFs
Injections (s.c.) between PND1
and 4. Ovaries collected on
PND5
Mouse (CD1) [60] Newborn ovaries cultured 3
days with BPA
Mouse (CD1) [161]
Injections (s.c.) between PND1
and 4. Ovaries collected on
PND5
Sheep [59]
Newborns received 5 daily s.c.
injections and ovaries collected
at PND40 and 90
Mouse (ICR/Jcl) [57]
Pregnant females treated with
BPA. F1 pups collected at PND
3, 5, 7
Mouse (CD1) [118]
Pregnant females exposed
during third trimester
(GD100-term)
Rhesus monkey [160]
Altered steroidogenesis In utero exposure through
drinking water of pregnant
females from day 6 of
pregnancy
Rat (SD) [69] Granulosa cells cultured with
BPA for 48 h
Porcine [162]
Females exposed daily from
gestation day 6 until labour
(gavage), followed by dosage of
pups from PND1 until PND90
Rat (SD) [163] Theca-interstitial cells and
granulosa cells cultured with
BPA
Rat (SD) [164]
Granulosa cells cultured for
72 h with BPA
Porcine [165]
↑ apoptosis and oocyte loss s.c. injections between PND1
and 4. Ovaries collected on
PND5
Mouse (CD1) [60] Granulosa cells cultured with
BPA
Mouse (B6C3F1) [166]
GV, germinal vesicle; i.p., intraperitoneal; s.c., subcutaneous; COCs, cumulus–oocyte complexes; SD, Sprague Dawley; PND, post-natal day.
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Table  7
Comparison of in vivo and in vitro effects of MEHP on the ovary.
Effect of MEHP In vivo In vitro
Study Species Paper Study Species Paper
Inhibited follicle growth.
Reduced number of antral
follicles and/or CL
Adult females were dosed daily
by gavage for 1–12 days
Rat (SD) [85] Pre-antral follicles cultured
individually for 10 days in
MEHP
Rat [173].
Antral follicles cultured with
MEHP for 96 h
Mouse (CD1) [174]
Pre-antral follicles from PND14
rats cultured for 48 h with
MEHP
Rat (SD) [133]
Antral follicles cultured with
MEHP for 24–96 h
Mouse (CD1) [175]
↑ number of mature follicles Pregnant females exposed via
oral gavage to MEHP. Females
in litter collected on ﬁrst day of
estrous cycle
Mouse (C57/Bl6) [172]
↑ atretic antral follicles Pregnant females received
daily doses of DEHP by gavage
from day 6 p.c. to lactation day
21
Rat (Wistar) [176]
Suppressed estradiol
production in granulosa cells of
pre-ovulatory follicles
Adult females were dosed daily
by gavage for 1–12 days
Rat (SD) [85] Granulosa cells from adult rat
ovaries cultured with MEHP for
48  h
Rat (Fisher 344) [177]
Antral follicles cultured with
MEHP for 96 h
Mouse (CD1) [174]
Granulosa cells cultured with
MEHP
Human [178]
Pre-antral follicles from PND14
rats cultured for 48 h with
MEHP
Rat (SD) [133]
Increased estradiol levels in
serum
Pregnant females exposed via
oral gavage to MEHP. Females
in litter collected on ﬁrst day of
estrous cycle
Mouse (C57/Bl6) [172]
Reduced aromatase expression Pregnant females exposed via
oral gavage to MEHP. Females
in litter collected on ﬁrst day of
estrous cycle
Mouse
(C57/Bl6)
[172] Granulosa cells from adult
ovaries cultured with MEHP for
48  h
Rat (Fisher 344) [177]
Granulosa cells cultured with Human [178]
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as formulated around the same time as DES but was consid-
red less potent. Exposure to BPA is ubiquitous, because it is
sed in combination with other chemicals in the manufacturing
f polycarbonate plastic and resins and is one of the highest-
olume chemicals produced worldwide [148,149]. BPA is used in
he manufacturing of polycarbonate, epoxy and corrosion resistant
olyester–styrene resins used to make food containers, tableware,
ental sealants and the lining of food cans [150,151]. Due to the
ster bonds in BPA-based polymers, they are subject to leaching
hich increases environmental exposure [152,153]. Analysis of
uman urine samples in the United States has shown that BPA is
resent in around 95% of urine samples (>0.1 ng/ml) [154] and since
PA is rapidly metabolised [155], this implies that humans are con-
inuously exposed to BPA probably through more than one source.
elationships between the degree of BPA exposure and ovarian
ysfunction, such as polycystic ovary syndrome [156] and recur-
ent miscarriage [157] have been suggested. BPA is also a selective
R modulator (SERM) and several studies have demonstrated its
ndocrine disrupting actions in both in vivo and in vitro (Table 6).
tudies that have investigated the effects of BPA both in vitro and
n vivo, have overall reported consistent effects: an increase in
eiotic defects, especially at higher doses, altered steroidogenesis,
elayed cyst breakdown and increased apoptosis in BPA exposed
emales/cultured ovaries [52,131,158]. Within that, there is some
iscrepancy to the exact details of the meiotic defects where some
tudies report aneuploidy following BPA exposure [51,52] whereasMEHP
another study reports no aneuploidy, but an induction of meiotic
arrest [53].
4.2.2. Mono(2-ethylhexyl)phthalate (MEHP)
The plasticiser MEHP is the major active metabolite of DEHP,
the most abundantly produced phthalate ester and the most potent
reproductive toxicant of the phthalates [167]. Phthalates are used
in the manufacturing of products such as packaging materials, food
wraps, medical devices including tubing, blood bags and disposable
medical examination gloves, and children’s toys to increase their
ﬂexibility [167]: over time, phthalates can leach from the plastic.
Due to their lipid-soluble and volatile nature, they are ubiqui-
tous environmental contaminants and humans are daily exposed to
phthalates from a wide variety of sources [168]. MEHP can cross the
placenta, and it is therefore possible that effects might occur from
exposure in utero. A group of factory-working women who were
chronically exposed to phthalates were shown to have increased
numbers of miscarriages and decreased pregnancy rates [169]. A
later study carried out on pregnant women living near a plastic
manufacturer also found a correlation between the phthalate lev-
els in their urine and pregnancy complications [170]. Mother and
foetus may  also be exposed to DEHP through every-day beauty
and consumer products [167]. In 2005, the European Union banned
phthalates with potential reproductive toxicity in all toys and child-
care objects [171]. Studies carried out on the effects of MEHP on
the pre- and post-natal ovary suggest that phthalates can induce
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Table 8
Comparison of in vivo and in vitro effects of DDT on the ovary.
Effect of DDT In vivo In vitro
Study Species Paper Study Species Paper
↑ expression of VEGF, Flk-1 and IGF-1 Females treated with DDE at
PND28 and 31. Ovaries
collected at PND50
Rat [186] Granulosa cells treated after
72 h in culture for 24 h with
DDE
Human [186]
↑ progesterone synthesis Granulosa cells cultured with
DDE
Porcine [187]
↓ progesterone synthesis Granulosa cells from
pre-pubertal gilts cultured
with DDE for 48 h
Porcine [188]
Granulosa cultured with DDE
for 24 h
Porcine [189]
↑ proliferation of granulosa cells Granulosa cells from
pre-pubertal gilts cultured
Porcine [188]
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dverse responses in females at all stages of development, with
n vivo and in vitro studies reporting consistent results, namely that
he main effect in adult females is suppressed estradiol production
y the ovary, most likely through suppression of aromatase activ-
ty (Table 7). A few studies reported opposite ﬁndings, for example,
oyer and Hixon [172] reported that PND56 females exposed in
tero had elevated serum estradiol levels (as opposed to the major-
ty of ﬁndings that reported reduced estradiol levels). However,
stradiol levels in the same females were signiﬁcantly reduced
ompared with controls by PND365.
.3. Organochlorine pesticides
.3.1. Dichlorodiphenyltrichloroethane
DDT)/dichlorodiphenyldichloroethylene (DDE)
DDT is used in a variety of agricultural fertilizers, house-
old insecticide sprays and parasitic medications. It has the
bility to persist in the environment and accumulate in the
ood chain [179]. It has been reported to result in reproduc-
ive abnormalities in wildlife, with a strong association found
etween dichlorodiphenyldichloroethylene (DDE), the most per-
istent metabolite of DDT, and egg shell thinning in predatory birds
180]. Exposure of female rabbits to DDT has been reported to lead
o decreased fertilisation rate as well as pre- and post-implantation
mbryonic loss [87]. DDE is ubiquitous and can be found in vari-
us human tissues, as well as serum and follicular ﬂuid [181–183],
uggesting that DDE has direct access to the oocyte. Higher DDE
evels in follicular ﬂuid of women undergoing IVF were associated
ith lower fertilisation rates [183], although the precise mecha-
ism through which DDE affects the ovary is unknown. Another
tudy suggested an association between DDE and polycystic ovary
yndrome (PCOS) [184]. Even though the use of DDT was discon-
inued in North America in 1972, it is still used, e.g., in Mexico as
 way of controlling malaria, and therefore is still able to enter the
nvironment [185]. The only study into both in vitro and in vivo
ffects of DDT on the ovary reported increased VEGF, Flk-1 and
GF-1 expression following treatment. Another study reported an
ncreased proliferation of granulosa cells, but several in vitro studies
ooking at progesterone synthesis do not report consistent effects
Table 8).
.3.2. Methoxychlor (MXC)
MXC  is an insecticide that was developed to replace DDT as it isonsidered less toxic [130,190], none-the-less, it has been found to
ffect the reproductive system at all stages of development [191]. It
s metabolised to mono-hydroxy MXC  in the body [192], and ovaries
f adult mice exposed to MXC  have been reported to contain higherwith DDE for 48 h
numbers of large atretic follicles, and have lower weight than con-
trol ovaries [191]. It has been debated whether these pesticides
(MXC/DDT) have the ability to impair fertility by directly acting
on the ovaries and affecting the meiotic progression of oocytes, or
whether they affect fertility indirectly due to action on the geni-
tal tract [193]. In vivo and in vitro studies on the effects on MXC
have produced consistent results (Table 9), reporting reduced folli-
cle growth and increased follicle atresia. This consistency between
in vivo and in vitro studies strongly indicates that the effects are
direct.
4.4. Occupational chemicals
4.4.1. 4-Vinylcyclohexene diepoxide (VCD)
VCD is an occupational chemical, an epoxide metabolite of
4-vinylcyclohexene (VCH). The VCH family of compounds are
occupational-hazard chemicals released into the environment at
low concentrations as by-products of the synthesis of plasticisers,
ﬂame retardants and rubber. VCD has been shown to selec-
tively deplete the rodent ovary of primordial and primary follicles
[197,198]. Daily treatments of VCD in mice and rats results in
primordial and primary follicle depletion, greatly reducing the
number of follicles that can be recruited for the formation of antral
follicles, thus subsequently affecting E2 secretion [199]. However,
only rodents are able to metabolise VCH to its active form VCD, and
since human exposure to VCH and its metabolites is minimal, VCH
has been considered as a model toxicant for reproductive toxico-
logy studies and for studying their effects on primordial follicle loss
[200]. All studies on the effects of VCD on the ovaries, in vitro and
in vivo, report consistent results: reduced numbers of pre-antral
follicles and an increase in apoptosis (Table 10).
4.4.2. Polychlorinated biphenyls (PCBs)
PCBs are pollutants that were generated on a large scale com-
mercially until their production was  banned in the 1970s [203]. PCB
contamination was  ﬁrst detected when environmental samples
were being screened for DDT and other environmental compounds
[204]; they have since been detected in the environment world-
wide. They are also used in the industrial community due to their
stabile and lipophilic properties [205]. This adds to their persistent
contamination in the environment, since they can accumulate in
food chains [35]. Furthermore, due to their lipophilic properties,
they can accumulate in adipose tissues, breast milk and are able to
cross the placenta. This means that the offspring can be exposed
to high concentrations of PCBs during pre- and post-natal develop-
ment [206]. PCBs and their congeners have been shown to affect the
reproductive system of several species [35]. One of the congeners,
A. Stefansdottir et al. / Reproductive Toxicology 49 (2014) 117–135 127
Table  9
Comparison of in vivo and in vitro effects of MXC  on the ovary.
Effect of MXC  In vivo In vitro
Study Species Paper Study Species Paper
↓ follicle growth/↓ antral
follicles
Females received daily s.c.
injections of MXC
Rat (SD) [81] Antral follicles from PND30 to
35 females were cultured for
96 h with MXC
Mouse (C57BL/6) [129]
Antral follicles were cultured
for 96 h with mono-OH
Mouse (CD1) [192]
↑ AMH positive follicles Female rats received daily s.c.
injections of MXC
Rat (SD) [81]
↑ follicle atresia Females received MXC  by oral
gavage for 14 days
Rat [194] Antral follicles from PND30 to
35 females were cultured for
96 h with MXC
Mouse (C57BL/6) [129]
Females received daily i.p. MXC
injections for 20 days
Mouse (CD1) [195]
Neonatal females received 14
daily i.p. injections of MXC.
Ovaries collected at 3, 6 and 12
months
Mouse (ND4 Swiss Webster) [196]
↓ progesterone synthesis Granulosa cells from
pre-pubertal gilts were
collected and cultured for 48 h
with MXC
Porcine [188]
Granulosa cells were exposed Porcine [189]
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,3′,4,4′-tetrachlorobiphenyl (TCB), is believed to act as an ovarian
oxicant through AhR-binding and consequently altering steroido-
enic pathways in the ovary [35].
Few in vitro studies have been carried out on the effects of
CBs on the ovary, therefore the only correlation between in
itro and in vivo studies relates to examining the effects on mei-
tic division of oocytes, with a decreasing percentage of oocytes
eaching metaphase II when ovaries were exposed to PCBs, demon-
trated in vivo in the mouse model and in vitro in the bovine
odel (Table 11). Other ﬁndings, such as decreased ovary weight,
ncreased follicle atresia and decreased follicle numbers show con-
istency between in vivo experimental approaches.
.5. Phyto-estrogens
.5.1. Genistein
Genistein is a naturally occurring isoﬂavone found in soy, with
he main human route of exposure through the consumption of soy
roducts or soy-based infant formula [35]; it is also taken as a form
f hormone replacement therapy by post-menopausal women. It
as received much scientiﬁc interest since it was  discovered that it
ad a negative effect on fertility in ewes [213]. Genistein has been
hown to have weak estrogenic and anti-estrogenic properties and
o induce cell differentiation [214]. Its actions are thought to result
able 10
omparison of in vivo and in vitro effects of VCD on the ovary.
Effect of VCD In vivo 
Study Species 
↓ number of primordial,
primary and secondary follicles
Daily i.p. injections for 30 days
to  PND28 females
Rat (F344) 
PND28 females received single
i.p. injection
Rat (F344) 
PND28 females received daily
i.p. injections
Rats and mi
↑ apoptosis Daily i.p. injections between
PND4 and 19
Rat (F344) 
.p., intraperitoneal; PND, post-natal day.to MXC  for 24 h
mainly from binding to ERs due to structural homology with E2
[215]. There are only two studies that appear to ﬁnd similar effects
in vitro and in vivo, with both studies ﬁnding that germ cell nest
nest breakdown was inhibited when neonatal mouse ovaries were
exposed to genistein: other effects have all been reported in only
one model (Table 12).
5. Comparison of results from in vivo and in vitro studies
Despite a wide range of study designs, which can vary in terms
of species, dosage routes and concentrations, timing and duration
of exposure, as well as whether single or repeated doses of com-
pounds are used, there are a substantial number of in vitro studies
showing near-identical effects to those found in vivo (Table 13).
There are however, instances where different effect/s are observed,
either between in vivo and in vitro studies, or despite the simi-
larity in the model used (Table 14). Possible explanations include
the compound having off target effects that could lead to a sec-
ondary effect on the ovaries in vivo but not in vitro. Alternatively,
the effects of a compound might not follow a normal dose–response
relationship; exposure to a compound at a low dose can have
a different, even a more signiﬁcant effect on the ovaries, than
exposure to higher concentrations [162,196]. Thus, low concen-
tration of BPA stimulated granulosa cell E2 production, whereas it
In vitro
Paper Study Species Paper
[199] PND4 ovaries cultured with
VCD for 1, 2 or 8 days
Rat (F344) [132]
[128] PND4 ovaries cultured with
VCD for 1 or 15 days
Rat (F344) [128]
ce [201]
[202] PND4 ovaries cultured for 15
days with VCD
Rat (F344) [202]
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Table 11
Comparison of in vivo and in vitro effects of PCB on the ovary.
Effect of PCB In vivo In vitro
Study Species Paper Study Species Paper
↓ ovary weight Pregnant females exposed to
PCBs. F1 females sacriﬁced on
PND21 or 84
Mouse (CD1) [203]
↑ follicular atresia Pregnant females exposed to
PCBs. F1 females sacriﬁced on
PND21 or 84
Mouse (CD1) [203]
↓ % of oocytes reaching
metaphase II/impaired
fertilisation
Pregnant females exposed to
PCBs. F1 females sacriﬁced on
PND21 or 84
Mouse (CD1) [203] COCs were exposed to
Arochlor-1254
Bovine [207]
↓ follicle numbers Females received i.p. injections
on day 13 p.c. F1 females
sacriﬁced on PND28
Mouse (C57/B1) [208]
Pregnant females injected (i.p.)
between 7 and 13 d.p.c.
Females sacriﬁced on
PND24/25
Rat (Long–Evans) [209]
Altered steroidogenesis Granulosa and theca cells
cultured with PCB126 or
PCB153
Porcine [210]
Co-cultures of granulosa and
theca cells were supplemented
with PCB
Porcine [211]
Co-cultures of ovarian theca Porcine [212]
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iV, germinal vesicle; i.p., intraperitoneal; s.c., subcutaneous; COCs, cumulus–oocyt
as inhibited by higher concentrations [162]. Effects of reproduc-
ive toxicants can also be time-dependent, with different effects
bserved between single-dose studies and those where animals
eceived repeated doses [218].
. Regulatory requirements for reproductive toxicological
esting
Most countries have statutory bodies regulating the test-
ng of potentially toxic compounds. Agencies such as EFSA (the
able 12
omparison of in vivo and in vitro effects of genistein on the ovary.
Effect of genistein In vivo 
Study Species 
Lowered or inhibited E2
production
Inhibited P4 production 
↓ testosterone and cAMP levels
(no effect on E2)
Inhibited nest breakdown Neonates received s.c.
injections of genistein between
PND1 and 5
Mouse (CD1) 
↑ atretic follicles Females received s.c. day of
genistein from PND18 to 20
Rat (Wistar) 
↓ follicle numbers Females received s.c. injections
of  genistein from PND18 to 20
Rat (Wistar) 
↑ MOFs Neonates dosed orally with
genistein from PND1 to 5
Mouse (C57B
Neonates received s.c.
injections of genistein
Mouse 
Females were dosed orally
with genistein from PND1 to 5
Rat (SD) 
.p., intraperitoneal; s.c., subcutaneous; SD, Sprague Dawley; PND, post-natal day.and granulosa cells were
exposed for 48 h with PCB
plexes; PND, post-natal day.
European Food Safety Authority), USEPA and FDA (the Food and
Drug Administration), were created for the purpose of protec-
ting human health and the environment by providing scientiﬁc
advice and by communicating on risks associated with the food
chain. The pharmaceutical industry also has rigorous regulatory
testing requirements, controlled by the EMA  (European Medi-
cal Agency), FDA (USA) and PMDA (Pharmaceuticals and Medical
Devices Agency, Japan). The guidelines are laid out in the core
tripartite harmonised guideline issued by the International Confer-
ence on Harmonisation of Technical Requirements for Registration
In vitro
Paper Study Species Paper
Granulosa cells cultured in
presence of genistein
Porcine [215]
Granulosa cells cultured in
presence of genistein
Porcine [215]
Follicles isolated from PND14
females and cultured for 5 days
with genistein
Rat (SD) [138]
[30] Ovaries from PND1 females
cultured for 7 days with
genistein
Mouse (CD1) [216]
[217]
[217]
L/6) [58]
[31]
[56]
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Table  13
Consistent results from comparisons of in vivo and in vitro experiments.
Comparable results between in vivo
and in vitro
Compound References
In vivo In vitro
↑ number of polyovular follicles DES [55] [143]
Inhibited germ cell nest breakdown GEN [30] [216]
↓ number of pre-antral follicles VCD [128,199] [128,132]
↑ apoptosis VCD [202] [202]
↓ follicle growth and fewer antral
follicles
MXC [81] [129,192]
↑ follicle atresia MXC  [194–196] [129]
Suppressed E2 production in
pre-ovulatory follicles
MEHP [85] [133,174,177]
Inhibited follicle growth
↓  number of antral follicles/CL
MEHP [85] [130,133,173]
Meiotic defects BPA [52,59] [131,159]
Altered steroidogenesis BPA [69] [131,162,164]
↑ apoptosis BPA [60] [166]
Stromal damage DXR [145] [145]
↑ apoptosis in oocytes DXR [145,146] [145,147]
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f Pharmaceuticals for Human Use (ICH) (S5) 1993 which provides
uidance on tests for reproductive toxicity [221].
.1. Regulation of pharmaceuticals and agrochemicals
In the pharmaceutical industry the majority of reproductive tox-
city testing is carried out in vivo. Potential toxic effects on both
ale and female fertility, foetal and post-natal development must
e taken into consideration. Reproductive toxicology testing fol-
ows guidelines issued by the ICH as well as by The Organisation
or Economic Co-operation and Development (OECD), with the aim
f creating standardised reproductive toxicology tests [44,222].
he ICH M3  (S5) guideline contains a description of the testing
oncept and recommendations, especially those addressing pre-
ating treatment duration and suggested observations to assess
or reproductive toxicity [221]. It deﬁnes the periods of treatment
o be used in animals to assess for reproductive risk: fertility,
mplantation through organogenesis to closure of the hard palate
nd the pre- and post-natal period through to the end of lacta-
ion. This allows speciﬁc identiﬁcation of stages of the reproductive
ycle that are at risk following human exposure to medicinal com-
ounds.
Preclinical designs to assess effects of potential toxicants on there-natal ovary are fairly similar between pharmaceutical com-
ounds and agrochemicals, but they differ in that pharmaceutical
ompanies analyse effects on long-term outcome, such as preg-
ancy after exposure in utero, whereas agrochemical testing also
able 14
onﬂicting results from in vivo and/or in vitro experiments.
Compound Effect 
Genistein Lowered PMF  numbers 
Increased PMF  numbers 
DDT Suppressed progesterone synthesis 
Increased progesterone synthesis 
MEHP Suppressed estradiol production 
Increased estradiol production 
DES Decelerated follicular development 
Accelerated follicular development 
DES Increased testosterone levels 
Decreased testosterone levels [134] [135]
includes a more detailed qualitative and quantitative histological
assessment of the primordial follicle pool following pre-natal expo-
sure.
6.2. Regulation of environmental compounds
In 1996 the U.S. congress, through the Food Quality Protection
Act (FQPA) and the Safe Drinking Water Act Amendments (SWDA),
directed USEPA to develop a screening system that uses scientiﬁ-
cally relevant information to examine whether certain compounds
can have hormonal effects in humans. The fertility and reproduc-
tion study protocol includes exposure of male and female rodents
prior to mating and throughout the mating period. The testing pro-
cess involves a two-tiered screening system, where the ﬁrst aims to
identify chemicals with the potential to interact with the endocrine
system, and the second aims to determine endocrine-related effects
caused by each individual chemical, gathering information about
their effects at different doses.
In 2013, the Scientiﬁc Committee (SC) of EFSA delivered a con-
sidered opinion on the existing information relating to the testing
and assessment on EDCs. The SC concluded that although a com-
plete range of standardised assays are available to test for endocrine
modalities in mammals and ﬁsh, although no single assay will
provide all the information required to decide whether a substance
falls into the ED category. The SC therefore expressed a need to fur-
ther develop the screens and test methods in order to generate
Study type References
In vivo [217]
In vivo [219]
In vitro [188]
In vitro [187]
In vivo and In vitro [85,133,174,177,178]
In vivo [172]
In vivo [59,142]
In vivo [55,60]
In vivo [220]
In vitro [138]
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Table 15
Pros and cons of in vivo compared to in vitro studies.
In vitro In vivo
Pro Con Pro Con
Highly controlled, i.e.,  exposure window,
concentration of compound and stage of
follicle growth
Will never tell the ‘whole story’ Best way  of predicting the ‘real
life’ situation
Difﬁcult to assess exactly how much an
animal is exposed to through the
placenta
Can  study a speciﬁc follicle type/stage Do not pick up on effects on
the reproductive tract
Can pick up effects on the
reproductive tract
Compounds can still be passed through
breast milk
Good for assessing direct effects of a
compound on the ovary
Do not pick up any effects on
the HPG axis
Can pick up detect effects on
the HPG axis
Compounds can persist in the animal
long after exposure
The  only procedure required for the animal
is  culling for tissue collection
Does not take into account
metabolism of chemical
Metabolism can be considered
– are compounds being
detoxiﬁed?
Requires more animal procedures than
the in vitro method
Pre-natal testing does not require exposure
to an animal that is not of interest to the
study
An effect in vitro does not
necessarily mean that the same
effect will be observed in vivo
Extensive use over decades
demonstrates its effectiveness
Pre-natal testing requires exposure to
the mother–an animal that may not be
of interest for the study
Easier  to assess whether it targets germ Can be used with ease to study
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Allows for higher throughput, including
testing of complex chemical mixtures
ufﬁcient data for identifying and assessing endocrine disrupting
roperties [223].
.3. Limitations of regulatory testing
Since EDC and pharmaceutical exposure can occur in the form
f individual chemicals or as chemical mixtures, it has proven
ifﬁcult to establish which situation causes more harm to repro-
uctive function, in particular because the effects might not become
vident until years later [11]. Furthermore, different periods of vul-
erability mean that a foetus might not be affected by a chemical
n the same way as an adult, making the testing of such chemicals
n reproductive function difﬁcult, yet that much more crucial.
The large majority of regulatory testing outlined above requires
n vivo experiments, using end-points such as pregnancy, implan-
ation and number of offspring, parameters that do not identify any
otential effects on the primordial follicle pool. Consequently, cur-
ent in vivo study designs might not pick up long-term effects on
he primordial follicle pool since it may  not affect immediate ovu-
ation rates and subsequent pregnancies, but might have longer
erm consequences on reproductive lifespan. On the other hand it
s also possible that an effect seen in the neonatal ovary may, in fact,
orrect itself in later life [224]. Furthermore, testing of chemicals
n vivo is time consuming and costly.
To date, in vitro models have been used primarily as a prelim-
nary or secondary screening protocol for toxicity testing, but the
ack of an alternative test system to available in vivo study designs
as been commented on Refs. [44,225,226]. Non-mammalian
pecies including zebraﬁsh, frogs, Caenorhabditis elegans and yeast
ave been found useful in regulatory toxicity testing as they offer
umerous advantages such as rapid development, ease and cost
f maintenance and high fecundidy [183,227,228]. However, to
ate, these models have primarily been used identify the molecular
argets of EDCs, to study toxicogenomics, to screen for oestrogen,
ndrogen and thyroid hormone disruption, or for threshold mea-
urements: as such, they are not ideal models for investigating
eproductive effects of toxicants and are not accepted models for
egulatory testing in the pharmaceutical industry [227,229]. This
as lead to an increased demand for adequate mammalian in vitro
odels that may  be used to gain an insight into the mechanisms of
hemical exposure and pinpoint potentially hazardous products on
eproductive function. As can be seen in the section above, in vitro
ultures have made a useful and powerful contribution to the ﬁeld
f reproductive toxicology testing. Not all regulatory works have
o be carried out in vivo and there is a strong case for consideringtransgenerational effects
in vitro testing to replace some of the currently required in vivo
tests.
7. Conclusions
Animals, including humans, are exposed to a very wide range
and number of compounds and chemical mixtures in their life-
time. Consequently, it is becoming increasingly crucial to develop
and improve the in vivo assessments and in vitro culture techniques
necessary to elucidate the toxic effects of pharmaceuticals and EDCs
on the ovary, to allow for faster screening of potential developmen-
tal and/or reproductive toxicants. The type and length of analysis
chosen for female reproductive toxicology research requires care-
ful consideration. The main pros and cons of in vitro compared with
in vivo studies are outlined in Table 15.
The key point of in vivo studies is to assess the potential toxic
risk of a drug on the body, when administered at a therapeutic
dose. Although this is more representative of the ‘real life’ situa-
tion, it can also be difﬁcult for in vivo studies to assess how much is
reaching the gonads, since compounds can be detoxiﬁed, activated
or eliminated in the body. Calculations to determine the amount
of compound reaching the gonads are complex and vary between
species and life stage. The method of exposure also needs careful
consideration as subcutaneous injections and oral ingestions of the
same amount of the same compound will not necessarily result
in the same ovarian exposure [230,231]. Other issues reproductive
toxicologists face when using in vivo studies include attempting to
limit the duration of exposure to a single dose of compound, since
some compounds can, for example, persist in the animal. Expo-
sure of compounds can change due to mobilisation of maternal
body reserves during pregnancy [232] or can be passed through
breast-milk a long time after the exposure window, making it difﬁ-
cult to predict the precise time and duration of exposure [35,230].
In vivo studies often use end-points such as pregnancy, implanta-
tion and number of offspring, which are parameters that do not
identify the site of action, the mechanism(s) of toxic damage or the
effect on the primordial follicle pool. However, female reproduc-
tive function requires effective communication between the ovary,
the neuroendocrine system, the hypothalamic–pituitary–gonadal
(HPG) axis and the reproductive tract, and in vivo studies will be
able to detect toxic effects on any of these systems, which could
result in a secondary effect on the gonads. For example, effects on
the oestrogen-dependent endometrium, could subsequently lead
to ovary-independent infertility [37,57]. One drawback of in vitro
studies is, therefore, that, although they can be useful for assessing
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irect effects on the ovary, they cannot account for any indirect
ction that might modulate hormone-signalling pathways such as
he HPG axis. Studies carried out in vitro are also unable to take
etabolism into consideration and care must be taken when exam-
ning effects of a compound that has no effect until it has been
etabolised. This is the case with DEHP, which is administered
n vitro as its active metabolite MEHP [167]. Even if a compound has
emonstrated interference with receptor binding/hormone pro-
uction in vitro, the same activity may  not be observed in vivo
233]. Despite this, in vitro models such as the ones described in
ection 4 are a promising area in toxicology, allowing pragmatic
nd mechanistic studies of action of reproductive toxicants and are
ble to reduce the number of animals required for in vivo stud-
es. In vitro systems are proving to be an invaluable preliminary
ethod to investigate direct effects of potentially harmful com-
ounds because it is practicable to test a very large dose-range
rom sub-environmental right up to toxicological levels. This holds
ery true for the female reproductive system, especially where
ppropriate care has been taken to administer doses that reﬂect
uman exposure levels in at least part of the dose–response curve
esign. Crucially, they require relatively little time to yield pre-
ise answers, and can cover various, yet speciﬁc, stages of ovary
nd follicle development. In vitro studies allow scientists to exam-
ne the precise mechanisms of action of a reproductive toxicant on
he different stages of growth and development, as well as to pin-
oint whether a speciﬁc chemical targets the stroma, the oocyte,
he somatic compartment of the follicle, or the follicle as a whole.
To summarise, in vitro studies are proving to be an invalu-
ble part of reproductive toxicology, to enable clear analysis of
hether a compound acts directly or indirectly on the ovarian folli-
le. Although they are less useful for studying indirect toxic effects
n the reproductive system, they still do have great potential to
rovide an important preliminary or secondary screening protocol
or toxicology testing alongside in vivo studies. The combination of
n vivo and in vitro work is a powerful one to detect and understand
echanisms of damage to the ovary, its follicles and oocytes, and
heir consequence for adult fertility and subsequent generations.
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